HUTCHMED (China) (HCM) Revenue (2015 - 2021)

HUTCHMED (China) (HCM) posted quarterly Revenue of $146.6 million for Q4 2021, up 79.75% quarter-over-quarter from $81.6 million in Q1 2021.

HUTCHMED (China) (HCM) Revenue (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HCM) has reported Revenue for 6 consecutive years, with $146.6 million the latest figure, recorded in Q4 2021.

In Q4 2021, Revenue changed N/A year-over-year to $146.6 million; the TTM figure through Dec 2021 stood at $334.9 million (changed N/A YoY), while the FY2025 annual figure was $70.5 million, up 3689.67% from the prior year.
Revenue climbed to $146.6 million in Q4 2021 per HCM's latest filing, from $81.6 million in the prior quarter.
Across five years, Revenue topped out at $146.6 million in Q4 2021 and bottomed at $49.3 million in Q3 2019.
Historically, Revenue has averaged $62.8 million across 4 years, with a median of $52.7 million in 2018.
Annual changes were most pronounced in 2019 — Revenue declined 16.09% — and 2021, when it surged 58.15%.
HUTCHMED (China)'s Revenue stood at $53.1 million in 2018, then grew by 0.44% to $53.3 million in 2019, then gained by 3.47% to $55.2 million in 2020, then surged by 165.6% to $146.6 million in 2021.
Business Quant data shows HCM's Revenue at $146.6 million in Q4 2021, $81.6 million in Q1 2021, and $55.2 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Haleon	43.87 Bn	42.91 Bn	-	-
2	Teva Pharmaceutical Industries	43.30 Bn	39.64 Bn	2.15 Bn	4.14 Bn
3	Zoetis	31.74 Bn	30.06 Bn	1.05 Bn	2.47 Bn
4	Takeda Pharmaceutical	28.74 Bn	22.95 Bn	5.10 Bn	7.65 Bn
5	United Therapeutics	22.26 Bn	19.60 Bn	683.80 Mn	783.30 Mn
6	Viatris	18.85 Bn	17.96 Bn	1.46 Bn	3.76 Bn
7	Neurocrine Biosciences	15.67 Bn	15.28 Bn	935.80 Mn	959.00 Mn
8	Elanco Animal Health	12.15 Bn	11.62 Bn	798.00 Mn	1.37 Bn
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-	-
10	HUTCHMED (China)	2.17 Bn	2.17 Bn	-	-

Download Data